Medical Encyclopedia |
|
Other encyclopedia topics: | A-Ag Ah-Ap Aq-Az B-Bk Bl-Bz C-Cg Ch-Co Cp-Cz D-Di Dj-Dz E-Ep Eq-Ez F G H-Hf Hg-Hz I-In Io-Iz J K L-Ln Lo-Lz M-Mf Mg-Mz N O P-Pl Pm-Pz Q R S-Sh Si-Sp Sq-Sz T-Tn To-Tz U V W X Y Z 0-9 |
Contents of this page: | |
|
|
Alternative Names Return to top
Acquired qualitative platelet disorders; Acquired disorders of platelet functionDefinition Return to top
Acquired platelet function defects are diseases or conditions that cause the blood elements needed for blood clotting (platelets) to not work properly. The term "acquired" means these diseases or conditions are not inherited, but instead develop independently in a person.
Causes Return to top
With platelet disorders, there may be too many or too few platelets, or platelets that do not function well. Any platelet disorder affects blood clotting.
These disorders can be caused by diseases that are present at birth (congenital), or they may develop because of another disease or condition. In many cases, the platelet count may be normal or even high, but there will be evidence of a bleeding disorder.
Disorders that can cause problems in platelet function include:
Other causes include:
Symptoms Return to top
Exams and Tests Return to top
Treatment Return to top
Treatment is aimed at the cause of the problem.
Outlook (Prognosis) Return to top
Treating the cause of the problem usually corrects the defect.
Possible Complications Return to top
When to Contact a Medical Professional Return to top
Call your health care provider:
Prevention Return to top
Using medications carefully can reduce the risk of drug-related acquired platelet function defects. Treating other disorders may also reduce the risk. Some cases are not preventable.
References Return to top
McMillan R. Hemorrhagic disorders: Abnormalities of platelet and vascular function. In: Goldman L, Ausiello D, eds. Cecil Medicine. 23rd ed. Philadelphia, Pa: Saunders Elsevier;2007:chap 179.
Update Date: 3/2/2009 Updated by: David C. Dugdale, III, MD, Professor of Medicine, Division of General Medicine, Department of Medicine, University of Washington School of Medicine; and Yi-Bin Chen, MD, Leukemia/Bone Marrow Transplant Program, Massachusetts General Hospital. Also reviewed by David Zieve, MD, MHA, Medical Director, A.D.A.M., Inc.